Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mechanisms of acquired resistance to osimertinib are more heterogeneous than those to first- and second-generation TKIs, including EGFR C797S, acquired KRAS, and targetable gene fusions.
“mechanisms of acquired resistance to osimertinib are more heterogeneous, and include EGFR C797S, acquired KRAS, and targetable gene fusions.”
From Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [97]
Cited by
Sorted by citations
Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438 · see citing works
Self-citationSchoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411 · see citing works
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311 · see citing works
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115 · see citing works
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88 · see citing works
Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0346 · Cited by 85 · see citing works
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04451-4 · Cited by 56 · see citing works
- Authors
- Ramalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., Todd, A., Markovets, A., Barrett, J. C., Chmielecki, J., & Gray, J.
- Affiliations
- Emory University (US)
- Jilin Province Tumor Hospital (CN)
- Tongji University (CN)
- National Cancer Center Hospital (JP)
- Osaka International Cancer Institute (JP)
- Yonsei University (KR)
- Chang Gung University (TW)
- Hospital de Sant Pau (ES)
- Maidstone and Tunbridge Wells NHS Trust (GB)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Moffitt Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Pages
- viii740
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2898171786
- Cited by
- 366
- References
- 0
- Citations by year
- 2026: 15 · 2025: 33 · 2024: 39 · 2023: 37 · 2022: 68 · 2021: 67 · 2020: 62 · 2019: 43 · 2018: 2
- FWCI
- 32.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- osimertinib, acquired drug resistance, EGFR mutation, non-small cell lung cancer, FLAURA trial, resistance mechanisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
